Immunocore presents three-year overall survival data from the KIMMTRAK Phase 3 trial - Immunocore Hldgs (NASDAQ:IMCR)

Data published in New England Journal of Medicine and presented as a late breaking abstract in mini oral session at ESMO Congress 2023 KIMMTRAK demonstrated long-term survival benefit in HLA-A*02:01 positive

Related Keywords

United States ,Australia ,Canada ,Oxfordshire ,United Kingdom ,Ukraine ,Rockville ,Western Australia ,Josepm Piulats ,Immunocore Imm ,Alexandern Shoushtari ,Marcus Butler ,Sophie Piperno Neumann ,Mohammed Dar ,Clayton Robertson ,Exchange Commission ,European Union ,Head Of Communications ,Linkedin ,Immunocore Holdings ,Exchange Commission On ,Twitter ,European Society For Medical Oncology ,New England Journal ,European Society ,Medical Oncology ,Immunocore Chief Medical ,Against Cancer ,Hazard Ratio ,Release Syndrome ,Product Characteristics ,Private Securities Litigation Reform Act ,Annual Report ,